PEACCEL co-authored a critical review on VHH structural modelling approaches with its academic partners
18 July 2022
VHH, i.e., VH domains of camelid single-chain antibodies, are very promising therapeutic agents due to their significant physicochemical advantages compared to classical mammalian antibodies. Unfortunately, most VHHs do not have 3D structures. This review presents the most extensive overview of structure prediction methods applied for the 3D modelling of a given VHH sequence (a total of 21). AlphaFold 2 and NanoNet appear to be the best tools to predict a structural model of VHH from its sequence.
PEACCEL and SYNTHELIS have signed a strategic partnership to increase the chances of success of your drugs
12 May 2022
PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.
Read more..
PEACCEL has just received the award “Life Sciences AI company of the Year” from CorporateLiveWire !
27 August 2021
PEACCEL listed in The Digest of Global AI in Pharma Investment
4 August 2021
PEACCEL is listed in The Digest of Global AI in Pharma Investment.https://www.linkedin.com/posts/alina-timoshenkova-5b0a6364_top-countries-in-ai-for-drug-discovery-sector-activity-6828674970089078784-xobr/
PEACCEL mentioned as a AI start-up to watch by NVIDIA
6 April 2021
PEACCEL mentioned as a AI start-up to watch by NVIDIA.Three Trends for Healthcare AI Startups To Watch Renee Y. | 19 mars 2021
https://www.linkedin.com/pulse/three-trends-healthcare-ai-startups-watch-renee-yao
PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).
6 April 2021
PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).